Legal & General Group PLC Sigilon Therapeutics, Inc. Transaction History

Legal & General Group PLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.48 - $0.86 $590 - $1,058	-1,231 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$4.42 - $10.61 $2,665 - $6,397	603 Added 96.02%	1,231 $7,000
Q2 2021 Aug 12, 2021	SELL	$9.15 - $20.17 $1,418 - $3,126	-155 Reduced 19.8%	628 $7,000
Q1 2021 May 17, 2021	BUY	$18.76 - $40.91 $14,689 - $32,032	783 New	783 $17,000

Ticker SGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,399,300
Description
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.